TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
Study: NCT00686556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
Study: NCT00686556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
Study: NCT04241978

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure with general information about osteoarthritis
Description: Participants of the control group will be given a brochure with general information about osteoarthritis of the hip, knee, ankle and foot instead of the PtDA
Study: NCT04349592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Study: NCT00686556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Beginning on Day -3 pre-transplant maintaining a level of \>200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
Study: NCT01698307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment Algorithm
Description: The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Step-care Algorithm
Description: Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
Study: NCT01648556

Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests and bone marrow biopsy repeated
Description: Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.
Study: NCT03870594

Intervention type: DIAGNOSTIC_TEST
Intervention: glycated hemoglobin
Description: hemoglobin A1c level in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: glycated hemoglobin
Description: hemoglobin A1c level in blood
Study: NCT04349592

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Oral, one tablet three times a day for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules
Description: Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Study: NCT01798732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
Description: One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
Study: NCT00669942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
Study: NCT03457779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV
Study: NCT03940183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin Succinate
Description: the experimental group will use trelagliptin succinate 100 mg for 24weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: the placebo Comparator groups use placebo oral tablet for 24weeks
Study: NCT02507037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gum+PEG
Description: chew sugarless gum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: polyethylene glycol
Description: 2L PEG
Study: NCT01004198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL PEG-Hb solution in lactated electrolyte solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL PEG-Hb solution in lactated electrolyte solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers Lactate solution
Description: Ringers Lactate solution for Injection
Study: NCT00680238

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Human derived FSH
Description: Customized for each patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human derived FSH
Description: Customized for each patient
Study: NCT04389437

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ophthalmological exam
Description: OCT-A and AO

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ophthalmological exam
Description: OCT-A and AO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmological exam
Description: OCT-A and AO

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure measurement before the ophthalmological exam

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure measurement before the ophthalmological exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Description: Blood pressure measurement before the ophthalmological exam
Study: NCT02571907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Branch Endovascular Graft-Iliac Bifurcation,
Description: Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrium iCAST™
Description: Implantation of Atrium iCAST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Flex AAA Endovascular Graft
Description: Implantation of the Zenith Flex Endovascular Graft
Study: NCT00532675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: PAN 5 mg and PAN 20 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: PAN 5 mg and PAN 20 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: PAN 5 mg and PAN 20 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: PAN 5 mg and PAN 20 mg capsules

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5mg or 25 mg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5mg or 25 mg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5mg or 25 mg

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5mg or 25 mg
Study: NCT01337999

Intervention type: OTHER
Intervention: blood draws
Description: 5 blood draws during ovulatory menstrual cycles in premenopausal women
Study: NCT04552145

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: standard decompression surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
Study: NCT03844711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical diaphragmatic stimulation (TEDS)
Description: * Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: - Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: - Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: - Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: - Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
Study: NCT00000460

Intervention type: BEHAVIORAL
Intervention: Low intensity exercise

Intervention type: BEHAVIORAL
Intervention: High intensity exercise
Study: NCT03816540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRV and respiratory coherence biofeedback
Description: Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HRV and respiratory coherence biofeedback
Description: Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
Study: NCT02508558

Intervention type: OTHER
Group type: OTHER
Intervention: motion perception and locomotor operation performance measurements

Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight
Study: NCT04015375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Description: Topical gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
Description: Topical gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Description: Topical gel
Study: NCT04605705

Intervention type: COMBINATION_PRODUCT
Intervention: Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.
Description: Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
Study: NCT02739633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: 125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Study: NCT00669942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AIN457
Study: NCT00686556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: 5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched related donor bone marrow
Description: Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched related donor bone marrow
Description: Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched related donor bone marrow
Description: Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched related donor bone marrow
Description: Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched related donor bone marrow
Description: Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
Study: NCT02314793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2205
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2205
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2205
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2205
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01552902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruzasvir
Description: Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
Study: NCT01552902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dosing in the AM for 6 weeks
Study: NCT03892421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Injection
Description: Cytarabine 2000 mg/m² qd 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim 0.3 MG/ML
Description: One subcutaneous injection daily for 5 days
Study: NCT03216382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.